Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions

Bibliography

• Stone KM. Human papillomavirus infection and genital warts. Update on epidemiology and treatment. Clin Infect Dis 1995;20:S91-7
   PubMed Web of Science ®Google Scholar
• Schmook T, Nindl I, Ulrich C, et al. Viral warts in organ transplant recipients: new aspects in therapy.Br J Dermatol 2003;149 (Suppl66):20-4
   PubMed Web of Science ®Google Scholar
• Bobrowska K, Kaminski P, Cyganek A, et al. Multiple neoplastic lesions of the lower genital tract in a human papilloma virus-infected kidney-pancreas allograft recipient: a case report. Transplant Proc 2005;37:2093-5
   PubMedGoogle Scholar
• Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. Int J Colorectal Dis 2005;22:1-5
   PubMedGoogle Scholar
• Hyckel P, Schleier P, Meerbach A, et al. The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients. Med Microbiol Immunol 2003;192:171-6
   PubMedGoogle Scholar
• Schneider A, Kinsky LA. Natural history and epidemiological features of genital HPV infection. IARC Sc Publ 1992;119:25-52
   PubMedGoogle Scholar
• Kiviat NB. Human papillomavirus and hepatitis viral infections in human immunodeficiency virus-infected persons. In: De Vita VT, Hellman S, Rosenberg SA editors. AIDS Etiology, Diagnosis, Treatment and Prevention, 4th edn. Lippincott-Raven, Philadelphia, 1997.p. 281-94
   Google Scholar
• Pruvost C, Penso-Assathiany D, Bachot N, et al. Risk factors for cutaneous wart onset in transplant recipients. Ann Dermatol Venereol 2002;129:291-93
   PubMedGoogle Scholar
• Ramsay HM, Fryer AA, Reece S, et al. Clinical risk factors associated with non melanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36:167-76
   PubMed Web of Science ®Google Scholar
• Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-92
   PubMed Web of Science ®Google Scholar
• Soler C, Chardonnet Y, Allibert P, et al. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol 1993;101:286-91
   PubMedGoogle Scholar
• Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 1992;73:2653-60
   PubMed Web of Science ®Google Scholar
• Laytragoon-Lewin N, Nilsson PJ, Castro J, et al. Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous carcinoma patients. Anticancer Res 2007;27:4473-79
   PubMedGoogle Scholar
• Kiviat NB, Critchlow CW, Holmes KK, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men.AIDS 1993;7(1):43-9
   PubMedGoogle Scholar
• Surawicz CM, Critchlow C, Sayer J, et al. High grade anal dysplasia in visually normal mucosa in homosexual men: seven cases. Am J Gastroenterol 1995;90:1776-8
   PubMedGoogle Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the economic annual burden to preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmaeconomics 2005;23(11):1107-22
   PubMedGoogle Scholar
• Garden JM, O′banion MK, Shelnitz LS, et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. JAMA 1988;259:1199-202
   PubMed Web of Science ®Google Scholar
• Garden JM, O′banion MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol).Arch Dermatol 2002;138:1303-7
   PubMed Web of Science ®Google Scholar
• Sawchuk WS, Felten RP. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989;21:41-9
   PubMed Web of Science ®Google Scholar
• Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995;32:436-41
   PubMed Web of Science ®Google Scholar
• Lipke MM. An armamentarium of wart treatments. Review. Clin Med Res 2006;4(4):273-93
   PubMedGoogle Scholar
• Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV infected patients. AIDS 2002;16(3):447-50
   PubMedGoogle Scholar
• Nathan M, Hickey N, Mayuranathan L, et al. Treatment of anal human papillomavirus-associated disease: a long term outcome study. Int J STD AIDS 2008;19(7):445-9
   PubMed Web of Science ®Google Scholar
• Runfola MA, Weber TK, Rodriguez-Bigas MA, et al. Photodynamic therapy for residual neoplasms of the perineal skin. Dis Colon Rectum 2000;43:499-502
   PubMedGoogle Scholar
• Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomavirus. Antiviral Res 2004;63:141-51
   PubMedGoogle Scholar
• Bonnez W, Oakes D, Bailey-Farchione A, et al. A randomized, double-blind, placebo-controlled trial of systemically administered interferon-alpha, -beta or –gamma in combination with cryotherapy of the treatment of condylomata acuminatum. J Infect Dis 1995;171:1081-89
   PubMedGoogle Scholar
• Arrese J, Paquet P, Claessens H, et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001;28(3):131-4
   PubMed Web of Science ®Google Scholar
• Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach of the treatment of cervix intraepithelial neoplasia grade III (CINIII). J Med Virol 2000;60:205-9
   PubMed Web of Science ®Google Scholar
• De Clercq E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and pyrimidines. Biochem Pharmacol 1991;42:963-72
   PubMed Web of Science ®Google Scholar
• Cihlár T, Votruba I, Horska K, et al. Metabolism of 1-(s)-(3-hydroxy-2-phosphonomethoxypropyl)-cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commu 1992;57:661-72
   Google Scholar
• Ho HT, Woods KL, Bronson JJ, et al. Intracellular metabolism of antiherpes agent (s)-1[3-hydroxy-2(phosphonylthoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202
   PubMed Web of Science ®Google Scholar
• Cundy KC, Lynch G, Shaw J-P, et al. Biochemical pharmacology of acyclic nucleotide analogue. Ann N Y Acad Sci 1990;616:398-407
   PubMedGoogle Scholar
• De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-96
   PubMed Web of Science ®Google Scholar
• Cundy KC, Lynch G, Shaw J-P, et al. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr Eye Res 1996;15:569-76
   PubMed Web of Science ®Google Scholar
• Spanos WC, El-Deiry M, Lee JH. Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity. Ann Otol Rhinol Laryngol 2005;111(11):840-46
   Google Scholar
• Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2000;12:397-408
   PubMed Web of Science ®Google Scholar
• Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (s)-1[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 1999;43:1198-205
   PubMedGoogle Scholar
• De Clercq E, Andrei G, Balzarini J, et al. Antitumor potential of acyclic nucleoside phophonates. Nucleosides Nucleotides 1999;18:759-71
   PubMedGoogle Scholar
• Liekens S, Andrei G, Vandeputte M, et al. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res 1998;58(12):2562-7
   PubMedGoogle Scholar
• Johnson JA, Gangemi JD. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrob Agents Chemother 2003;47(6):2022-26
   PubMedGoogle Scholar
• Cundy KC, Li ZH, Hichcock MJ, Lee WA. Pharmakokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos 1996;24:738-44
   PubMedGoogle Scholar
• Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human deficiency virus-infected subjects. Antiviral Res 1996;29:153-61
   PubMed Web of Science ®Google Scholar
• Wachsman M, Petty B, Jaffe H, et al. Phase I trial of a new anti-cytomegalovirus agent (s)-1-[3-hydroxy-2 (phosphonylmethoxy)-propyl]cytosine (HPMPC) in HIV infected volunteers.Antiviral Res 1994;109(1):93
   Google Scholar
• Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res 1997;35:113-22
   PubMed Web of Science ®Google Scholar
• Cundy KC, Petty BP, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in HIV-infected patients. Antimicrob Agents Chemother 1995;39:1247-52
   PubMed Web of Science ®Google Scholar
• Aspe E, Guy RH, Lee WA, et al. Optimization of in vitro flux through hairless mouse skin cidofovir, a potent nucleotide analog. J Pharm Sci 1995;84:750-4
   PubMed Web of Science ®Google Scholar
• Okamoto H, Muta K, Hashida M, Sezaki H. Percutaneous penetration of acyclovir through excised mouse & rat skin. Effect of vehicle and percutaneous penetration enhancer. Pharm Res 1990;7:64-8
   PubMed Web of Science ®Google Scholar
• Kern ER, Palmer J, Vogt PE, et al. Efficacy and pharmacokinetics of topical HPMPC in a genital herpes model.Antiviral Res 1995;26:A341
   Google Scholar
• Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002;73:661-2
   PubMed Web of Science ®Google Scholar
• Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papilloma virus infections with an acyclic nucleoside phosphonate analogue (letter). N Engl J Med 1995;333:943-44
   PubMed Web of Science ®Google Scholar
• Martinelli C, Farese A, Del Mistro A, et al. Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HPV infection. JEADV 2001;15:568-9
   Google Scholar
• Stragier I, Snoeck R, De Clercq E, et al. Local treatment of HPV-induced skin lesions by Cidofovir.J Med Virol 2002;67(2):241-5
   PubMedGoogle Scholar
• Bonatti H, Aigner F, De Clercq E, et al. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007;20:238-46
   PubMedGoogle Scholar
• Coremans G, Wyndaele J, Dockx S, et al. Eradication of intra-anal condylomata acuminata and histologically dysplasia with combined intralaesional cidofovir and coagulations.Gastroenterology 2008;134:A-318(M1009)
   Google Scholar
• Hengge UR, Tietze G. Succesful treatment of recalcitrant condyloma with topical cidofovir.Sex Transm Infect 2000;76:143
   PubMed Web of Science ®Google Scholar
• Schurmann D, Bergmann F, Temmesfeld-Wollbruck B, et al. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 2000;14:1075-6
   PubMed Web of Science ®Google Scholar
• Koonsaeng S, Verschraegen C, Freedman R, et al. Case Report. Succesful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J Med Vir 2001;64:195-98
   PubMedGoogle Scholar
• Snoeck R, Bossens M, Parent D, et al. Phase II double-blind placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33:597-602
   PubMed Web of Science ®Google Scholar
• Coremans G, Margaritis V, Snoeck R, et al. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis Colon Rectum 2003;46:1103-8
   PubMedGoogle Scholar
• Bischofberger N, Hitchcock MJM, Chen MS, et al. Cyclic HPMPC: an intracellular prodrug for HPMPC with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38:2387-91
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Drew WL, Glutzer E, et al. HPMPC: result of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96
   PubMed Web of Science ®Google Scholar
• Cundy KC, Li ZH, Lee WA. Effect of concomitant probeneed on the tissue distribution and urinary excretion of HPMPC in preclinical models.Pharm Res 1994;11 (Suppl):S-449
   Google Scholar
• Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues – a survey. Antiviral Res 2001;49(2):55-74
   PubMed Web of Science ®Google Scholar